# Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)

> **NCT00204633** · PHASE2 · COMPLETED · sponsor: **University Hospital Tuebingen** · enrollment: 108 (actual)

## Conditions studied

- Dysgerminoma

## Interventions

- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT00204633
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2009-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00204633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00204633, "Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00204633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*